HER2 Support Group Forums - View Single Post - Halozyme Announces Roche Doses First Patient In Phase 3 Clinical Trial With Subcutane

News · 10-22-2009, 08:10 PM

Halozyme Therapeutics, Inc. (Nasdaq:HALO) and Roche announced dosing of the first patient in a Phase 3 registration trial using Enhanze? technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche's anticancer biologic, Herceptin (trastuzumab).

More...

10-22-2009, 08:10 PM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,133	Halozyme Announces Roche Doses First Patient In Phase 3 Clinical Trial With Subcutane Halozyme Therapeutics, Inc. (Nasdaq:HALO) and Roche announced dosing of the first patient in a Phase 3 registration trial using Enhanze? technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche's anticancer biologic, Herceptin (trastuzumab). More...